Monograph: |
DOXIFLURIDINE
路 IMMUNOSUPPRESSIVE AGENTS
路 路
ANTIMETABOLITES
路 路 ANTINEOPLASTIC AGENTS
路 PYRIMIDINE NUCLEOSIDES
(6R)-FOLINIC ACID THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN (6R)-FOLINIC ACID IS COMBINED WITH DOXIFLURIDINE.
(6S)-5,6,7,8-TETRAHYDROFOLIC ACID THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN (6S)-5,6,7,8-TETRAHYDROFOLIC ACID IS COMBINED WITH DOXIFLURIDINE.
(R)-WARFARIN THE RISK OR SEVERITY OF BLEEDING CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH (R)-WARFARIN.
(S)-WARFARIN THE RISK OR SEVERITY OF BLEEDING CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH (S)-WARFARIN.
2-METHOXYETHANOL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 2-METHOXYETHANOL IS COMBINED WITH DOXIFLURIDINE.
4-HYDROXYCOUMARIN THE RISK OR SEVERITY OF BLEEDING CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH 4-HYDROXYCOUMARIN.
5-METHYLTETRAHYDROFOLIC ACID THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 5-METHYLTETRAHYDROFOLIC ACID IS COMBINED WITH DOXIFLURIDINE.
9-(N-METHYL-L-ISOLEUCINE)-CYCLOSPORIN A THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH 9-(N-METHYL-L-ISOLEUCINE)-CYCLOSPORIN A.
ABATACEPT THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ABATACEPT IS COMBINED WITH DOXIFLURIDINE.
ABETIMUS THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ABETIMUS IS COMBINED WITH DOXIFLURIDINE.
ACENOCOUMAROL THE RISK OR SEVERITY OF BLEEDING CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH ACENOCOUMAROL.
ACTEOSIDE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH ACTEOSIDE.
ADALIMUMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ADALIMUMAB IS COMBINED WITH DOXIFLURIDINE.
ADENOVIRUS TYPE 7 VACCINE LIVE THE RISK OR SEVERITY OF INFECTION CAN BE INCREASED WHEN ADENOVIRUS TYPE 7 VACCINE LIVE IS COMBINED WITH DOXIFLURIDINE.
AFELIMOMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AFELIMOMAB IS COMBINED WITH DOXIFLURIDINE.
ALDESLEUKIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALDESLEUKIN IS COMBINED WITH DOXIFLURIDINE.
ALDOSTERONE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALDOSTERONE IS COMBINED WITH DOXIFLURIDINE.
ALEFACEPT THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALEFACEPT IS COMBINED WITH DOXIFLURIDINE.
ALEMTUZUMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALEMTUZUMAB IS COMBINED WITH DOXIFLURIDINE.
ALTRETAMINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALTRETAMINE IS COMBINED WITH DOXIFLURIDINE.
AMSACRINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AMSACRINE IS COMBINED WITH DOXIFLURIDINE.
ANAKINRA THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ANAKINRA IS COMBINED WITH DOXIFLURIDINE.
ANTHRAX IMMUNE GLOBULIN HUMAN THE THERAPEUTIC EFFICACY OF ANTHRAX IMMUNE GLOBULIN HUMAN CAN BE DECREASED WHEN USED IN COMBINATION WITH DOXIFLURIDINE.
ANTHRAX VACCINE THE RISK OR SEVERITY OF INFECTION CAN BE INCREASED WHEN ANTHRAX VACCINE IS COMBINED WITH DOXIFLURIDINE.
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) IS COMBINED WITH DOXIFLURIDINE.
ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) IS COMBINED WITH DOXIFLURIDINE.
APREMILAST THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN APREMILAST IS COMBINED WITH DOXIFLURIDINE.
ARSENIC TRIOXIDE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ARSENIC TRIOXIDE IS COMBINED WITH DOXIFLURIDINE.
AZACITIDINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AZACITIDINE IS COMBINED WITH DOXIFLURIDINE.
AZATHIOPRINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AZATHIOPRINE IS COMBINED WITH DOXIFLURIDINE.
BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN THE RISK OR SEVERITY OF INFECTION CAN BE INCREASED WHEN BACILLUS CALMETTE-GUERIN SUBSTRAIN CONNAUGHT LIVE ANTIGEN IS COMBINED WITH DOXIFLURIDINE.
BACILLUS CALMETTE-GUERIN SUBSTRAIN DANISH 1331 LIVE ANTIGEN THE RISK OR SEVERITY OF INFECTION CAN BE INCREASED WHEN BACILLUS CALMETTE-GUERIN SUBSTRAIN DANISH 1331 LIVE ANTIGEN IS COMBINED WITH DOXIFLURIDINE.
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN THE RISK OR SEVERITY OF INFECTION CAN BE INCREASED WHEN BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN IS COMBINED WITH DOXIFLURIDINE.
BARICITINIB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BARICITINIB IS COMBINED WITH DOXIFLURIDINE.
BASILIXIMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BASILIXIMAB IS COMBINED WITH DOXIFLURIDINE.
BCG VACCINE THE RISK OR SEVERITY OF INFECTION CAN BE INCREASED WHEN BCG VACCINE IS COMBINED WITH DOXIFLURIDINE.
BECLOMETHASONE DIPROPIONATE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BECLOMETHASONE DIPROPIONATE IS COMBINED WITH DOXIFLURIDINE.
BEGELOMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH BEGELOMAB.
BELATACEPT THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BELATACEPT IS COMBINED WITH DOXIFLURIDINE.
BELIMUMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BELIMUMAB IS COMBINED WITH DOXIFLURIDINE.
BELINOSTAT THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BELINOSTAT IS COMBINED WITH DOXIFLURIDINE.
BENDAMUSTINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BENDAMUSTINE IS COMBINED WITH DOXIFLURIDINE.
BETAMETHASONE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BETAMETHASONE IS COMBINED WITH DOXIFLURIDINE.
BEVACIZUMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BEVACIZUMAB IS COMBINED WITH DOXIFLURIDINE.
BEXAROTENE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BEXAROTENE IS COMBINED WITH DOXIFLURIDINE.
BLEOMYCIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLEOMYCIN IS COMBINED WITH DOXIFLURIDINE.
BLESELUMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN DOXIFLURIDINE IS COMBINED WITH BLESELUMAB.
BLINATUMOMAB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLINATUMOMAB IS COMBINED WITH DOXIFLURIDINE.
BORTEZOMIB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BORTEZOMIB IS COMBINED WITH DOXIFLURIDINE.
BOSUTINIB THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BOSUTINIB IS COMBINED WITH DOXIFLURIDINE.
|